Alyeska Investment Group, L.P. Morpho Sys Ag Transaction History

Alyeska Investment Group, L.P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	BUY	$23.24 - $26.76 $447,788 - $515,611	19,268 Added 25.28%	95,490 $0
Q1 2019 May 15, 2019	BUY	$22.55 - $29.84 $546,206 - $722,784	24,222 Added 46.58%	76,222 $0
Q4 2018 Feb 14, 2019	SELL	$21.96 - $31.02 $17,370 - $24,536	-791 Reduced 1.5%	52,000 $1.32 Million
Q3 2018 Nov 14, 2018	SELL	$26.64 - $35.66 $1.62 Million - $2.17 Million	-60,829 Reduced 53.54%	52,791 $1.41 Million
Q2 2018 Aug 14, 2018	BUY	$25.15 - $30.6 $2.86 Million - $3.48 Million	113,620 New	113,620 $3.45 Million

11.3M

320K

1.1M

Ticker MOR
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 136,614,000
Market Cap $2.54B
Description
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

Stay updated on Alyeska Investment Group, L.P. with notifications on news.